A Phase 1 clinical study demonstrates that dual-target BCMA-CD19 CAR-T therapy (ICG318) can achieve sustained, drug-free remission and significant renal improvement in patients with refractory SLE and lupus nephritis, with follow-up extending up to six years.
A new study reveals that off-the-shelf CD19-targeted CAR-T cell therapy effectively treats relapsed systemic lupus erythematosus (SLE), achieving remission and kidney recovery. Discover how this innovative approach may revolutionize autoimmune disease treatment.
CAR T-cell therapy shows promise in treating refractory autoimmune rheumatic diseases by targeting CD19 for faster, more significant effects and potential drug-free remission.
CAR T-cell therapy is a personalized treatment. Feel free to contact us, find out whether CAR T-cell therapy is the right treatment for you or your loved one.
Whether you’re a patient, caregiver, or medical professional, our team can connect you with leading CAR-T treatment centers and clinical experts in China.
Fill out the form below and we’ll get back to you shortly with personalized support.